Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

Webb Nicholas J. A.; Lerner Gary; Warady Bradley A.; Dell Katherine M.; Greenbaum Larry A.; Ariceta Gema; Hoppe Bernd; Linde Peter; Lee Ho-Jin; Eldred Ann; Dufek Matthew B.

首页> 外文期刊>Pediatric nephrology: journal of the International Pediatric Nephrology Association >Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

【24h】

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

机译：宿享苏氏酶在3至5次慢性肾病儿童中的疗效和安全性

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Elevated intact parathyroid hormone (iPTH) levels can contribute to morbidity and mortality in children with chronic kidney disease (CKD). We evaluated the pharmacokinetics, efficacy, and safety of oral paricalcitol in reducing iPTH levels in children with stages 3-5 CKD.

机译：升高的完整甲状旁腺激素（IPTH）水平可以有助于慢性肾病（CKD）的儿童发病率和死亡率。我们评估了口腔蛋白质的药代动力学，疗效和安全性在减少3-5 CKD阶段的儿童的IPTH水平。

著录项

来源
《Pediatric nephrology: journal of the International Pediatric Nephrology Association》 |2017年第7期|共12页
作者
Webb Nicholas J. A.; Lerner Gary; Warady Bradley A.; Dell Katherine M.; Greenbaum Larry A.; Ariceta Gema; Hoppe Bernd; Linde Peter; Lee Ho-Jin; Eldred Ann; Dufek Matthew B.;
展开▼
作者单位

Univ Manchester Royal Manchester Childrens Hosp Manchester Acad Hlth Sci Ctr Dept Paediat;

Childrens Hosp Los Angeles Keck Sch Med Pediat Nephrol Los Angeles CA 90027 USA;

Childrens Mercy Hosp Div Pediat Nephrol Kansas City MO 64108 USA;

Case Western Reserve Univ Cleveland Clin Childrens Ctr Pediat Nephrol Cleveland OH 44106 USA;

Emory Sch Med Atlanta GA USA;

Univ Autonoma Barcelona Univ Hosp Vall dHebron Pediat Nephrol Barcelona Spain;

Univ Hosp Bonn Bonn Germany;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

AbbVie Inc N Chicago IL USA;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类儿科学;
关键词
Secondary hyperparathyroidism; Paricalcitol; Chronic kidney disease-mineral and bone disorder; Pediatric; Hypercalcemia;

机译：继发性甲状旁腺功能亢进;蛋白酸;慢性肾病 - 矿物和骨紊乱;儿科;高钙血症;

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [J] . Webb Nicholas J. A., Lerner Gary, Warady Bradley A., Pediatric nephrology: journal of the International Pediatric Nephrology Association . 2017,第7期

机译：宿享苏氏酶在3至5次慢性肾病儿童中的疗效和安全性
2. CLINICAL TRAIL SIMULATIONS OF THE EXTRAPOLATED PHARMACOKINETICS, SAFETY AND EFFICACY OF PARICALCITOL IN CHILDREN 2-9 YEARS OF AGE WITH CHRONIC KIDNEY DISEASE. [J] . Stodtmann S., Mostafa N. M., Dufek M. B. Clinical Pharmacology and Therapeutics . 2018,第Suppla1期

机译：慢性肾病2-9岁儿童外推药代动力学，外推药代动力学，安全性和疗效模拟。
3. Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease [J] . Tianzhao Han, Gong Rong, Dayong Quan, BioMed research international . 2013,第Pta2期

机译：荟萃分析：慢性肾病治疗继发性甲状旁腺功能亢进和蛋白尿的疗效和安全性
4. The Natural History of Chronic Kidney Disease Revisited-A 72-Month Mayo Health System Hypertension Clinic Practice-Based Research Network Prospective Report on End-Stage Renal Disease and Death Rates in 100 High-Risk Chronic Kidney Disease Patients: A Call for Circumspection [C] . Macaulay A.C. Onuigbo Conference on Peritoneal Dialysis . 2009

机译：慢性肾病的自然历史重新审议-A 72个月的MASO卫生系统高血压诊所的研究网络网络前期肾病和死亡率100个高危慢性肾病患者的死亡率：一个呼吁守则
5. The effect of paricalcitol on proteinuria in non-dialysis chronic kidney disease patients [D] . Hojs, Nina 2015

机译：蛋白酸对非透析慢性肾病患者蛋白尿的影响
6. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [O] . Nicholas J. A. Webb, Gary Lerner, Bradley A. Warady, -1

机译：Paricalcitol对3至5期慢性肾脏病患儿的疗效和安全性
7. Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease [O] . 2017

机译：帕立骨化醇对3至5期慢性肾脏病患儿的疗效和安全性

Efficacy and safety of paricalcitol in children with stages 3 to 5 chronic kidney disease

摘要

著录项

相似文献

相关主题

期刊订阅